M&A Deal Summary

Janssen Pharmaceuticals Acquires INCIVO

On November 20, 2013, Janssen Pharmaceuticals acquired life science company INCIVO from Vertex Pharmaceuticals for 152M USD

Acquisition Highlights
  • This is Janssen Pharmaceuticals’ 2nd transaction in the Life Science sector.
  • This is Janssen Pharmaceuticals’ 3rd largest (disclosed) transaction.
  • This is Janssen Pharmaceuticals’ 2nd transaction in the United States.

M&A Deal Summary
Date 2013-11-20
Target INCIVO
Sector Life Science
Buyer(s) Janssen Pharmaceuticals
Sellers(s) Vertex Pharmaceuticals
Deal Type Divestiture
Deal Value 152M USD

Target

INCIVO

United States
INCIVO is a prescription medicine used with the medicines peginterferon alfa and ribavirin to treat chronic (lasting a long time) hepatitis C genotype 1 infection in adults with stable liver problems, who have not been treated before or who have failed previous treatment.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Janssen Pharmaceuticals

Titusville, New Jersey, United States
Category Company
Founded 1973
Sector Life Science
DESCRIPTION

Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, provides medicines for an array of health concerns in several therapeutic areas, including: attention deficit hyperactivity disorder (ADHD), general medicine (acid reflux disease, infectious diseases), mental health (bipolar I disorder, schizophrenia), neurologics (Alzheimer’s disease, epilepsy, migraine prevention and treatment), pain management, and women’s health.

DEAL STATS #
Overall 2 of 4
Sector (Life Science) 2 of 4
Type (Divestiture) 1 of 2
Country (United States) 2 of 3
Year (2013) 1 of 1
Size (of disclosed) 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-07-15 Ortho Dermatologics

Skillman, New Jersey, United States

Ortho Dermatologics, Inc. is a provider of dermatologist recommended and prescribed skincare products RETIN-A MICRO, ERTACZO, and RENOVA.

Sell $345M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-03-19 XO1

Babraham, United Kingdom

XO1 Ltd. is an asset-centric virtual biopharmaceutical company. It is a developer of anti-thrombin antibody ichorcumab.

Buy -

Seller(S) 1

SELLER

Vertex Pharmaceuticals

Boston, Massachusetts, United States
Category Company
Founded 1989
Sector Life Science
Employees5,400
Revenue 9.9B USD (2023)
DESCRIPTION

Vertex Pharmaceuticals is a biotechnology company that aims to discover, develop, and commercialize innovative new medicines so people with serious diseases can lead better lives. Vertex Pharmaceuticals was founded in 1989 and is based in Boston, Massachusetts.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Divestiture) 1 of 2
Country (United States) 1 of 2
Year (2013) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2009-03-12 ViroChem Pharma

Laval, Quebec, Canada

ViroChem Pharma, Inc., is a pharmaceutical company focused on hepatitis treatments.

Buy $375M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-07-26 Vertex Pharmaceuticals - Lomibuvir & Merimepodib Inhibitors

Boston, Massachusetts, United States

Vertex Pharmaceuticals - Lomibuvir & Merimepodib Inhibitors is a development and commercialization rights to treat infectious disease with lomibuvir (VX-222), a non-nucleoside inhibitor of the HCV NS5B polymerase and merimepodib (VX-497), an inhibitor of inosine monosphosphate dehydrogenase with broad-spectrum antiviral properties.

Sell -
Mergr

Product

Company

Legal